1-20 of 24
Diana Abbott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Steven M. Bair, Mayur Narkhede, Zachary AK Frosch, Elise A. Chong, Daniel A. Ermann, Iris Isufi, Farrukh T. Awan, Julio C Chavez, Grace N Bosma, Diana Abbott
Journal: Blood
Blood (2023) 142 (Supplement 1): 68.
https://doi.org/10.1182/blood-2023-187113
Published: 2023
Journal Articles

Socioeconomic Status Is a Mediator of Overall Survival in Acute Myeloid Leukemia (AML)

Cassandra Duarte, Diana Abbott, Grace N Bosma, Christine M. McMahon, Jonathan A Gutman, Marc Schwartz, Daniel Pollyea, Maria L Amaya
Journal: Blood
Blood (2023) 142 (Supplement 1): 5176.
https://doi.org/10.1182/blood-2023-174996
Published: 2023
Journal Articles

A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center

Hunter Tolison, Cassandra Duarte, Glen Peterson, Grace N Bosma, Diana Abbott, Gemlyn George, Daniel Pollyea, Craig T. Jordan, Maria L Amaya
Journal: Blood
Blood (2023) 142 (Supplement 1): 3688.
https://doi.org/10.1182/blood-2023-179669
Published: 2023
Journal Articles

Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza

Diana Abbott, Grace Bosma, Christine M. McMahon, Marc Schwartz, Jonathan A. Gutman, Daniel A. Pollyea
Journal: Blood
Blood (2022) 140 (Supplement 1): 6181–6182.
https://doi.org/10.1182/blood-2022-169026
Published: 2022
Journal Articles

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Jonathan A. Gutman, Amanda C. Winters, Andrew Kent, Maria L. Amaya, Christine M. McMahon, Clayton Smith, Craig T Jordan, Brett M. Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffrey Schowinsky, Jennifer Tobin, Kelly O'Brien, Angela Falco, Elizabeth Taylor, Constance Brecl, Phuong Ho, Connor Sohalski, Jessica Dell-Martin, Olivia Ondracek, Diana Abbott, Daniel A. Pollyea
Journal: Blood
Blood (2022) 140 (Supplement 1): 3275–3276.
https://doi.org/10.1182/blood-2022-157802
Published: 2022
Journal Articles

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Alexander Hayden, Grace Bosma, Jonathan A. Gutman, Maria L. Amaya, Diana Abbott, Clayton Smith, Brett M. Stevens, Craig T. Jordan, Daniel A. Pollyea, Christine M. McMahon
Journal: Blood
Blood (2022) 140 (Supplement 1): 9163–9164.
https://doi.org/10.1182/blood-2022-171064
Published: 2022
Journal Articles

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Christine M. McMahon, Kellen Gil, Maria L. Amaya, Jonathan A. Gutman, Alexander Hayden, Marc Schwartz, Grace Bosma, Diana Abbott, Brett M. Stevens, Clayton Smith, Craig T Jordan, Daniel A. Pollyea
Journal: Blood
Blood (2022) 140 (Supplement 1): 6185–6186.
https://doi.org/10.1182/blood-2022-170168
Published: 2022
Journal Articles

Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Bradley M. Haverkos, Jasmine Zain, Manali K. Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Steven M. Bair, Jagar Jasem, Emily Berens, Clayton Smith, Diana Abbott, Pierluigi Porcu
Journal: Blood
Blood (2022) 140 (Supplement 1): 2308–2309.
https://doi.org/10.1182/blood-2022-168979
Published: 2022
Journal Articles

A Pilot Study Using Nivolumab in Combination with Standard of Care Chemotherapy in Newly Diagnosed Peripheral T-Cell Lymphomas

Brad Haverkos, Jasmine Zain, Manali Kamdar, Alexander Neuwelt, Steven M. Bair, Jagar Jasem, Emily Berens, Clayton Smith, Diana Abbott, Pierluigi Porcu
Journal: Blood
Blood (2021) 138 (Supplement 1): 2444.
https://doi.org/10.1182/blood-2021-152617
Published: 2021
Journal Articles

Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy

Amanda C. Winters, Grace Bosma, Diana Abbott, Mohd Minhajuddin, Craig T Jordan, Daniel A. Pollyea, Jonathan A. Gutman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3957.
https://doi.org/10.1182/blood-2021-154392
Published: 2021
Journal Articles

Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving CAR-T Cell Therapy

Gray Jodon, Meryl Colton, Diana Abbott, Anthony Cai, Brad M. Haverkos, Rustain Morgan, Manali Kamdar
Journal: Blood
Blood (2021) 138 (Supplement 1): 3879.
https://doi.org/10.1182/blood-2021-146613
Published: 2021
Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea
Journal: Blood
Blood (2020) 136 (Supplement 1): 9.
https://doi.org/10.1182/blood-2020-136120
Published: 2020
Journal Articles

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Shanshan Pei, PhD, Daniel A Pollyea, MD, Annika Gustafson, Mohammad Minhajuddin, PhD, Brett M. Stevens, PhD, Haobin Ye, PhD, Anagha Inguva, BSc, Maria L Amaya, MD PhD, Anna Krug, BS, Courtney L Jones, PhD, Biniam Adane, PhD, Amanda Winters, MD PhD, Nabilah Khan, Jessica Ponder, PhD, Jeffrey Schowinsky, Andrew Hammes, MS, Diana Abbott, PhD, Jason R Myers, MS, John M Ashton, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Haley E. Ramsey, PhDMSc, Michael R. Savona, MD, Stephen W. Fesik, PhD, Clayton Smith, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 185.
https://doi.org/10.1182/blood-2019-131390
Published: 2019
Journal Articles

Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

Neelam Mistry, MD, Diana Abbott, PhD, Japera Walker Wilkison, MA, Ajay Major, MDMBA, Brad M. Haverkos, MDMPH,MS, Manali Kamdar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4126.
https://doi.org/10.1182/blood-2019-129208
Published: 2019
Journal Articles

How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine

Diana Abbott, PhD, Andrew Hammes, MS, Jonathan A Gutman, MD, Daniel A Pollyea, MD, Clayton Smith, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5897.
https://doi.org/10.1182/blood-2019-126344
Published: 2019
Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Amanda Winters, MD PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Brett M. Stevens, PhD, Shanshan Pei, PhD, Jeffrey Schowinsky, Diana Abbott, PhD, Andrew Hammes, MS, Molly Nakic, Lindsey Lyle, Keri Halsema, Dwight Macero, PA-C, Alex Hirose, Chelsey Boggs, Angie Falco, Natalie Monson, Shirstine Rahkola, Sarah Wright, Tyler D'Ovidio, Clayton Smith, MD, Craig T Jordan, PhD, Daniel A Pollyea, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2638.
https://doi.org/10.1182/blood-2019-122120
Published: 2019
Journal Articles

PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia

Brett M. Stevens, PhDBS, Courtney L Jones, PhD, Amanda Winters, MDPhD, James Dugan, MD, Diana Abbott, PhD, Michael R. Savona, MD, Stephen W. Fesik, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 909.
https://doi.org/10.1182/blood-2018-99-119806
Published: 2018
Journal Articles

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Daniel A Pollyea, MD, Courtney L Jones, PhD, Brett M Stevens, PhD, Shanshan Pei, PhD, Angelo D'Alessandro, PhD, Rachel Culp-Hill, BS, Diana Abbott, PhD, Andrew Hammes, MS, James Dugan, MD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 432.
https://doi.org/10.1182/blood-2018-99-111507
Published: 2018
Journal Articles

Bone Marrow Cellularity and Recovery of Blood Counts after Venetoclax and Azacitidine in Elderly Acute Myeloid Leukemia Patients Unfit for Induction Chemotherapy

James Dugan, MD, Daniel A. Pollyea, MD, Diana Abbott, PhD, Theodore Schultheiss, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5086.
https://doi.org/10.1182/blood.V130.Suppl_1.5086.5086
Published: 2017
Journal Articles

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Daniel A. Pollyea, MD, Brett M. Stevens, PhD, Amanda Winters, MD PhD, Mohd Minhajuddin, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD FRCPC, Diana Abbott, PhD, Craig T. Jordan, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 181.
https://doi.org/10.1182/blood.V130.Suppl_1.181.181
Published: 2017